Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theratechnologies Inc T.TH

Alternate Symbol(s):  THTX

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.


TSX:TH - Post by User

Post by Biobobon Oct 13, 2022 11:37am
231 Views
Post# 35022407

On the positive side

On the positive sideOn the positive side they reinstated guidance and beat the conscensus, the said that they are moving forward with F8 and subcontracting their own bacterial water supply. Target 2024 for Nash and Lypo if they want to continue to have protection. The fact that Nash amendments are not settled yet may mean they might have partner interest in the original P3 agreed trial.  The Th1902 may not have yielded 2 positive outcome in one of the basket trial cancer type yet and recruitment could be slower than expected but like Wino said maybe patient dying off because of their advanced status not helping.  Anyway Marsolais said he has a Q1 traget for complete recruitment, I don't think he want's to have to explain he mislead us on this one.  Trying hard to be positive like Wino since SPCEO seems to be in a bad mood.
<< Previous
Bullboard Posts
Next >>